Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Found in translation of mTOR signaling.

Clohessy JG, Reschke M, Pandolfi PP.

Cell Res. 2012 Sep;22(9):1315-8. doi: 10.1038/cr.2012.85. Epub 2012 May 29.

2.

A novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1.

Tsai BP, Jimenez J, Lim S, Fitzgerald KD, Zhang M, Chuah CT, Axelrod H, Wilson L, Ong ST, Semler BL, Waterman ML.

Open Biol. 2014 Nov;4(11):140180. doi: 10.1098/rsob.140180.

3.

Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of rapamycin on protein synthesis.

Huo Y, Iadevaia V, Yao Z, Kelly I, Cosulich S, Guichard S, Foster LJ, Proud CG.

Biochem J. 2012 May 15;444(1):141-51. doi: 10.1042/BJ20112107.

PMID:
22428559
4.

The translational landscape of mTOR signalling steers cancer initiation and metastasis.

Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, Shokat KM, Rommel C, Ruggero D.

Nature. 2012 Feb 22;485(7396):55-61. doi: 10.1038/nature10912.

5.

YB-1 synthesis is regulated by mTOR signaling pathway.

Lyabin DN, Eliseeva IA, Ovchinnikov LP.

PLoS One. 2012;7(12):e52527. doi: 10.1371/journal.pone.0052527. Epub 2012 Dec 20.

6.

Evaluation of mTOR-regulated mRNA translation.

Iadevaia V, Wang X, Yao Z, Foster LJ, Proud CG.

Methods Mol Biol. 2012;821:171-85. doi: 10.1007/978-1-61779-430-8_10.

PMID:
22125065
7.

Albumin-induced epithelial-mesenchymal transition and ER stress are regulated through a common ROS-c-Src kinase-mTOR pathway: effect of imatinib mesylate.

Lee JY, Chang JW, Yang WS, Kim SB, Park SK, Park JS, Lee SK.

Am J Physiol Renal Physiol. 2011 May;300(5):F1214-22. doi: 10.1152/ajprenal.00710.2010. Epub 2011 Mar 2.

8.

Mammalian target of rapamycin signaling in the podocyte.

Inoki K, Huber TB.

Curr Opin Nephrol Hypertens. 2012 May;21(3):251-7. doi: 10.1097/MNH.0b013e3283520f38. Review.

PMID:
22388550
9.

Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity.

Huang S, Shu L, Easton J, Harwood FC, Germain GS, Ichijo H, Houghton PJ.

J Biol Chem. 2004 Aug 27;279(35):36490-6. Epub 2004 Jun 24.

10.

mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.

Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, Bosi A, Vannucchi AM; Associazione Italiana per la Ricerca sul Cancro AGIMM Gruppo Italiano Malattie Mieloproliferative.

PLoS One. 2013;8(1):e54826. doi: 10.1371/journal.pone.0054826. Epub 2013 Jan 31.

11.

Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth.

Rico C, Laguë MN, Lefèvre P, Tsoi M, Dodelet-Devillers A, Kumar V, Lapointe E, Paquet M, Nadeau MÈ, Boerboom D.

Carcinogenesis. 2012 Nov;33(11):2283-92. doi: 10.1093/carcin/bgs263. Epub 2012 Aug 7.

12.

Differential contribution of the MTOR and MNK pathways to the regulation of mRNA translation in meiotic and postmeiotic mouse male germ cells.

Messina V, Di Sauro A, Pedrotti S, Adesso L, Latina A, Geremia R, Rossi P, Sette C.

Biol Reprod. 2010 Oct;83(4):607-15. doi: 10.1095/biolreprod.110.085050. Epub 2010 Jun 23.

13.

S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnover.

Mieulet V, Roceri M, Espeillac C, Sotiropoulos A, Ohanna M, Oorschot V, Klumperman J, Sandri M, Pende M.

Am J Physiol Cell Physiol. 2007 Aug;293(2):C712-22. Epub 2007 May 9.

14.

A novel semisynthetic inhibitor of the FRB domain of mammalian target of rapamycin blocks proliferation and triggers apoptosis in chemoresistant prostate cancer cells.

Morad SA, Schmid M, Büchele B, Siehl HU, El Gafaary M, Lunov O, Syrovets T, Simmet T.

Mol Pharmacol. 2013 Feb;83(2):531-41. doi: 10.1124/mol.112.081349. Epub 2012 Dec 3.

15.

Inhibition of mTOR affects protein stability of OGT.

Park S, Pak J, Jang I, Cho JW.

Biochem Biophys Res Commun. 2014 Oct 17;453(2):208-12. doi: 10.1016/j.bbrc.2014.05.047. Epub 2014 May 22.

PMID:
24858682
16.

A longer and healthier life with TOR down-regulation: genetics and drugs.

Bjedov I, Partridge L.

Biochem Soc Trans. 2011 Apr;39(2):460-5. doi: 10.1042/BST0390460. Review.

PMID:
21428920
17.

Comparative effects of PP242 and rapamycin on mTOR signalling and NOTCH signalling in leukemia cells.

Ono A, Oike R, Okuhashi Y, Takahashi Y, Itoh M, Nara N, Tohda S.

Anticancer Res. 2013 Mar;33(3):809-13.

PMID:
23482748
18.

mTOR signaling pathway and mTOR inhibitors in cancer therapy.

Gomez-Pinillos A, Ferrari AC.

Hematol Oncol Clin North Am. 2012 Jun;26(3):483-505, vii. doi: 10.1016/j.hoc.2012.02.014. Epub 2012 Mar 31. Review.

PMID:
22520976
19.

Beyond control of protein translation: what we have learned about the non-canonical regulation and function of mammalian target of rapamycin (mTOR).

Malik AR, Urbanska M, Macias M, Skalecka A, Jaworski J.

Biochim Biophys Acta. 2013 Jul;1834(7):1434-48. doi: 10.1016/j.bbapap.2012.12.010. Epub 2012 Dec 29. Review.

PMID:
23277194
20.

mTOR inhibitor for the treatment of hepatocellular carcinoma.

Kudo M.

Dig Dis. 2011;29(3):310-5. doi: 10.1159/000327565. Epub 2011 Aug 9. Review.

PMID:
21829022
Items per page

Supplemental Content

Write to the Help Desk